Breakthroughs Blog Old
City of Hope has so many breakthroughs in cancer, diabetes and HIV/AIDS - and so many stories - that we've tailored our blog, Breakthroughs, to provide something for every reader. Whether the breakthroughs are about medical research, treatment advances or personal triumphs, they're all connected.
City of Hope's BMT survival rates exceed expectations for 15 consecutive years
February 14, 2020 | City of Hope
City of Hope’s bone marrow transplantation program has achieved a higher-than-expected survival rate based on a 2019 analysis by the Center for International Blood and Marrow Transplant Research.
Saswati Chatterjee, Ph.D., Seeks Cure for Hemophilia
February 21, 2018 | Katie Neith
Saswati Chatterjee, Ph.D., a professor in the Department of Surgery and member of Beckman Research Institute of City of Hope, thinks she may know a way to cure hemophilia A.
New Hire: Daniel Jae Kim
January 25, 2018 | City of Hope
Daniel Jae Kim, M.D., is based at City of Hope's South Pasadena facility and specializes in hematology and oncology.
Larry Kwak, M.D., Ph.D., Receives Grant for Promising Lymphoma Work
January 12, 2018 | Letisia Marquez
Larry Kwak, M.D., Ph.D., received a grant to support his work with mantle cell lymphoma from the Leukemia & Lymphoma Society, the world’s largest voluntary health organization dedicated to fighting blood cancer.
Multiple Myeloma CAR T Cell Trial to launch in 2017
April 3, 2017 | Travis Marshall
An upcoming phase 1 clinical trial at City of Hope will look at the effects of CAR T cells programmed to target a protein called CS-1, which is found on myeloma cells.
Researchers tackle two difficult-to-treat lymphomas
February 2, 2017 | Letisia Marquez
New study in the Journal of Clinical Oncology concludes that patients with relapsed or treatment-resistant double-hit and/or double-expressor lymphomas didn’t respond as well to the transplantation as diffuse large B-cell lymphoma patients who did not have those types of lymphoma.
Hodgkin Lymphoma Trial Results Promising
January 9, 2017 | Abe Rosenberg
Everything changed when a Hodgkin lymphoma patient joined a Phase II clinical trial examining the effectiveness of brentuximab vedotin (BV) after a failed transplant. The BV worked immediately, achieving a complete remission which, year after year, proved to be durable beyond anyone's expectations.
Steven T. Rosen, M.D. on the Latest Breakthroughs in Blood Cancer Treatment
December 16, 2016 | City of Hope
The long-term strategies offered by City of Hope’s Hematologic Malignancies (HM) Program have dramatically improved the lives of patients with leukemia, lymphoma, Hodgkin’s disease and multiple myeloma.
ASH 2016: Innovative new trials show promise for lymphoma and multiple myeloma patients
December 7, 2016 | City of Hope
Numerous clinical trials, which lay the groundwork for novel approaches to lymphoma and multiple myeloma therapies, could ultimately lead to new treatments that improve survival and quality of life for patients with those and other diseases. Additional studies give new insight into best practices for the treatment of various blood cancers.
Treatment for acute lymphoblastic leukemia patients has improved, but challenges persist
September 14, 2016 | Leti Marquez
Children with acute lymphoblastic leukemia (ALL) are going into remission at higher rates than ever before - thanks to better treatment that stems from leading-edge clinical trials - but adults with ALL still face significant hurdles in overcoming the disease.